Leukemia Clinical Trials in Phoenix

Showing 461-480 of 1,062 trials

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Pancreatic CancerBreast CancerGastric Cancer+13 more

NGM Biopharmaceuticals, Inc130 participantsStarted Mar 2022

Gilbert, Arizona, United States • Los Angeles, California, United States • Sarasota, Florida, United States +6 more locations

COMPLETEDPhase 3108 miles

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

NCT01877655

The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT will also be evaluated.

Cytomegalovirus (CMV)-Positive RecipientsAllogeneic, Hematopoietic Cell Transplant (HCT)

Astellas Pharma Global Development, Inc.514 participantsStarted Sep 2013

Birmingham, Alabama, United States • Tucson, Arizona, United States • San Francisco, California, United States +80 more locations

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Leukemia Trials in Other Cities

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Milademetan in Advanced/Metastatic Solid Tumors

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Other Conditions in Phoenix